an investigational drug developed for the treatment of asthma and scalp hair loss
setipiprant (inn; developmental code names act-129968, kyth-105) is an investigational drug developed for the treatment of asthma and scalp hair loss. it was originally developed by actelion and acts as a selective, orally available antagonist of the prostaglandin d2 receptor 2 (dp2). the drug is being developed as a novel treatment for male pattern baldness by allergan.
scalp hair loss
acting through dp2, pgd2 can inhibit hair growth, suggesting that this receptor is a potential target for bald treatment. a phase 2a study to evaluate the safety, tolerability, and efficacy of oral setipiprant relative to a placebo in 18- to 49-year-old males with androgenetic alopecia was compl
we are API powder supplier of setipiprant from china.